Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of Actuate Therapeutics (NASDAQ:ACTU) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Actuate Therapeutics in a research note on Wednesday, November 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.33.

Actuate Therapeutics Price Performance

Shares of Actuate Therapeutics stock opened at $2.86 on Friday. The stock has a market cap of $66.47 million, a price-to-earnings ratio of -3.29 and a beta of 0.10. The firm’s 50-day moving average is $4.88 and its 200 day moving average is $6.33. Actuate Therapeutics has a 1 year low of $2.73 and a 1 year high of $11.99.

Insiders Place Their Bets

In other Actuate Therapeutics news, Director Todd S. Thomson sold 280,000 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $5.80, for a total value of $1,624,000.00. Following the transaction, the director owned 904,795 shares of the company’s stock, valued at approximately $5,247,811. This represents a 23.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 69.34% of the company’s stock.

Institutional Investors Weigh In On Actuate Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ACTU. Voss Capital LP boosted its holdings in shares of Actuate Therapeutics by 213.2% in the third quarter. Voss Capital LP now owns 896,278 shares of the company’s stock worth $5,996,000 after buying an additional 610,138 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Actuate Therapeutics during the 4th quarter valued at $579,000. BIOS Capital Management LP increased its stake in shares of Actuate Therapeutics by 0.9% in the 3rd quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock worth $67,234,000 after purchasing an additional 84,917 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Actuate Therapeutics by 252.5% in the 2nd quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock worth $721,000 after purchasing an additional 84,561 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Actuate Therapeutics by 19.5% in the 3rd quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock worth $2,114,000 after purchasing an additional 51,546 shares during the period.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.